Literature DB >> 23047604

Doubly robust estimation, optimally truncated inverse-intensity weighting and increment-based methods for the analysis of irregularly observed longitudinal data.

Eleanor M Pullenayegum1, Brian M Feldman.   

Abstract

Longitudinal data arising from routine follow-up of patients will often have irregular measurement times. Existing methods for analysis include joint modelling of the outcome and measurement processes, and inverse-intensity weighting (IIW). This work extends previously proposed analysis of increments to the case of irregular follow-up, yielding a model for the increments that can be used as a stand-alone method. Furthermore, we propose two ways of combining the increments and IIW estimators. First, we use the increment model to select the truncation point for the inverse-intensity weights that minimises the mean squared error of the IIW estimator. Second, we use the increment model to augment the usual IIW estimating equations to form a doubly robust estimator. We evaluate the methods through simulation and apply these to a recent study of juvenile dermatomyositis.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23047604     DOI: 10.1002/sim.5640

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Independence conditions and the analysis of life history studies with intermittent observation.

Authors:  Richard J Cook; Jerald F Lawless
Journal:  Biostatistics       Date:  2021-07-17       Impact factor: 5.899

2.  On the Nature of Informative Presence Bias in Analyses of Electronic Health Records.

Authors:  Glen McGee; Sebastien Haneuse; Brent A Coull; Marc G Weisskopf; Ran S Rotem
Journal:  Epidemiology       Date:  2022-01-01       Impact factor: 4.822

3.  Linear Increments with Non-monotone Missing Data and Measurement Error.

Authors:  Shaun R Seaman; Daniel Farewell; Ian R White
Journal:  Scand Stat Theory Appl       Date:  2016-04-06       Impact factor: 1.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.